INM — Mentari Therapeutics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.75 | ||
| Price to Tang. Book | 6.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1079.76% | ||
| Return on Equity | -156.77% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Jun | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.09 | 4.14 | 4.6 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mentari Therapeutics, Inc., formerly InMed Pharmaceuticals Inc., is a biotechnology company developing therapies for migraine prevention. The Company's lead programs target PACAP, a newly validated target that is mechanistically independent from calcitonin gene-related peptide (CGRP). Its pipeline includes MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody designed to inhibit these complementary pathways with the potential to deliver superior outcomes for people with incomplete response to CGRP-targeted therapies.
Directors
- Eric Adams PRE (62)
- Andrew Hull NEC (62)
- Eric Hsu SVP (55)
- Michael Woudenberg COO (56)
- Nicole Lemerond IND (50)
- N. Netta Jagpal CFO (52)
- Neil Klompas IND (53)
- John Bathery DRC (56)
- Last Annual
- June 30th, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- May 19th, 1981
- Public Since
- June 21st, 2001
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 549,374
- Address
- 1445-885 West Georgia St., VANCOUVER, V6C 3E8
- Web
- https://www.inmedpharma.com
- Phone
- +1 6046697207
- Contact
- Colin Clancy
- Auditors
- CBIZ CPAs P.C.
Latest News for INM
Upcoming Events for INM
InMed Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2027 InMed Pharmaceuticals Inc Earnings Release
Similar to INM
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 02:20 UTC, shares in Mentari Therapeutics are trading at $13.21. This share price information is delayed by 15 minutes.
Shares in Mentari Therapeutics last closed at $13.21 and the price had moved by -23.64% over the past 365 days. In terms of relative price strength the Mentari Therapeutics share price has underperformed the S&P500 Index by -30.22% over the past year.
The overall consensus recommendation for Mentari Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMentari Therapeutics does not currently pay a dividend.
Mentari Therapeutics does not currently pay a dividend.
Mentari Therapeutics does not currently pay a dividend.
To buy shares in Mentari Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $13.21, shares in Mentari Therapeutics had a market capitalisation of $7.26m.
Here are the trading details for Mentari Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INM
Based on an overall assessment of its quality, value and momentum Mentari Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mentari Therapeutics is $19.40. That is 46.85% above the last closing price of $13.21.
Analysts covering Mentari Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mentari Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +104.86%.
As of the last closing price of $13.21, shares in Mentari Therapeutics were trading +8.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mentari Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $13.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mentari Therapeutics' management team is headed by:
- Eric Adams - PRE
- Andrew Hull - NEC
- Eric Hsu - SVP
- Michael Woudenberg - COO
- Nicole Lemerond - IND
- N. Netta Jagpal - CFO
- Neil Klompas - IND
- John Bathery - DRC